Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

In the Interim...

In the Interim... artwork

The Rumor of One Trial for Substantial Evidence

Dec 29, 202540 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of "In the Interim…", host Dr. Scott Berry and frequent co-host Dr. Kert Viele, Senior Statistical Scientist at Berry Consultants, analyze the potential shift in FDA regulatory policy from requiring two independent trials to accepting a single trial as sufficient for “substantial evidence” in drug approvals. Reflecting on the statutory and regulatory definitions originating with the 1962 Federal Food, Drug, and Cosmetic Act and 21 CFR 314.126, they dissect current and emerging interpretations, referencing recent statements by Dr. Martin Makary and coverage described in a STAT article. The conversation focuses on the scientific and statistical foundations of the two-trial threshold, challenges with dichotomous results, and how pooled evidence might increase efficiency and rigor. They discuss statistical implications including alpha thresholds, sample size effects, program power, and the consequences for clinical labeling. The episode also introduces Bayesian approaches as a method for integrating totality of evidence. Attention is given to both population breadth and the possible risks of a narrowed evidentiary base under a single-trial standard. Key Highlights Regulatory and historical context of “substantial evidence” since 1962 and current FDA directives. Industry practice: simultaneous Phase III trials, statistical power, and evidentiary replication. Criticism of binary, trial-level significance thresholds; merits of pooling or meta-analysis. Potential efficiency gains and tradeoffs with a more stringent alpha requirement for single trials. Strategic and operational effects on trial design, sample size, and label indications. Bayesian statistical approaches for full evidence integration, discussed as an analytical viewpoint.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Hosts

  • Scott Berry Host Feed-stated

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Can Borrowing Ever Increase Power?

    Nov 16, 202625 minAudio

    In this episode of "In the Interim…", Dr. Kert Viele, Director of Research at Berry Consultants, takes up a requested topic: published results showing that Bayesian borrowing of historical control data cannot increase...

    Credit the people on this episode

  2. Mailbag: Learning Healthcare, Multiplicities, and the Pace of Innovation

    Nov 9, 202647 minAudio

    In this mailbag episode of "In the Interim…", Dr. Scott Berry answers two listener questions and weighs in on the pace of innovation in clinical trial science. Asked what infrastructure a learning healthcare system...

    Credit the people on this episode

  3. Reflecting on EMA Reflections on Platform Trials

    Nov 2, 202644 minAudio

    In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele, Director of Research at Berry Consultants, review the European Medicines Agency's draft reflection paper on methodological aspects in...

    Credit the people on this episode

  4. Statistical Methodology Groups in the Pharmaceutical Industry

    Oct 19, 202656 minAudio

    In this episode of "In the Interim…", Scott Berry is joined by Jenny Devenport and Kaspar Rufibach of Merck Group, co-authors of the EFSPI Statistical Methodology Leaders paper "Statistical Methodology Groups in the...

    Credit the people on this episode

  5. A Discussion on Virtual Controls

    Oct 12, 202647 minAudio

    In this episode of "In the Interim…", Dr. Scott Berry shares the framework he presented at a CSRC regulatory science hackathon on digital twins and synthetic controls in cardiovascular clinical trials. He separates...

    Credit the people on this episode